Literature DB >> 12137567

Novel peptide inhibitors of Leishmania gp63 based on the cleavage site of MARCKS (myristoylated alanine-rich C kinase substrate)-related protein.

Sally Corradin1, Adriana Ransijn, Giampietro Corradin, Jacques Bouvier, Maria Belen Delgado, Jimena Fernandez-Carneado, Jeremy C Mottram, Guy Vergères, Jacques Mauël.   

Abstract

The zinc metalloprotease gp63 (leishmanolysin; promastigote surface protease) is expressed at high density at the surface of Leishmania promastigotes. Efficient non-toxic inhibitors of gp63 do not exist, and its precise role in parasite physiology remains unknown. MARCKS (myristoylated alanine-rich C kinase substrate) and MARCKS-related protein (MRP; MacMARCKS) are protein kinase C substrates in various cells, including macrophages. We reported previously that MRP is an excellent substrate for gp63. A major cleavage site was identified within the MRP effector domain (ED), a highly basic 24-amino-acid sequence, and the synthetic ED peptide (MRP(ED)) was shown to inhibit MRP hydrolysis. In the present study, MRP cleavage was used as an assay to measure the capacity of various MRP or MARCKS ED peptides to block gp63 activity. On a molar basis, MRP(ED) inhibited gp63 to a greater extent than two previously described gp63 inhibitors, o -phenanthroline and benzyloxycarbonyl-Tyr-Leu-NHOH. MARCKS(ED) analogues containing modifications in the gp63 consensus cleavage site showed significant differences in inhibitory capacity. As phosphorylation of ED serine residues prevented gp63-mediated MRP degradation, we synthesized a pseudophosphorylated peptide in which serine residues were substituted by aspartate (3DMRP(ED)). 3DMRP(ED) was a highly effective inhibitor of both soluble and parasite-associated gp63. Finally, MRP ED peptides were synthesized together with an N-terminal HIV-1 Tat transduction domain (TD) to obtain cell-permeant peptide constructs. Such peptides retained gp63 inhibitory activity and efficiently entered both macrophages and parasites in a Tat TD-dependent manner. These studies may provide the basis for developing potent cell-permeant inhibitors of gp63.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12137567      PMCID: PMC1222923          DOI: 10.1042/BJ20020386

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

Review 1.  Protein transduction: unrestricted delivery into all cells?

Authors:  S R Schwarze; K A Hruska; S F Dowdy
Journal:  Trends Cell Biol       Date:  2000-07       Impact factor: 20.808

2.  Phosphorylation-dependent conformational changes induce a switch in the actin-binding function of MARCKS.

Authors:  M R Bubb; R H Lenox; A S Edison
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

3.  Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides.

Authors:  Bradley R Kelemen; Kevin Hsiao; Said A Goueli
Journal:  J Biol Chem       Date:  2001-12-26       Impact factor: 5.157

4.  Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor.

Authors:  Phalgun B Joshi; Ben L Kelly; Shaden Kamhawi; David L Sacks; W Robert McMaster
Journal:  Mol Biochem Parasitol       Date:  2002-03       Impact factor: 1.759

Review 5.  Cross-talk unfolded: MARCKS proteins.

Authors:  Anna Arbuzova; Arndt A P Schmitz; Guy Vergères
Journal:  Biochem J       Date:  2002-02-15       Impact factor: 3.857

6.  Leishmania mexicana mutants lacking glycosylphosphatidylinositol (GPI):protein transamidase provide insights into the biosynthesis and functions of GPI-anchored proteins.

Authors:  J D Hilley; J L Zawadzki; M J McConville; G H Coombs; J C Mottram
Journal:  Mol Biol Cell       Date:  2000-04       Impact factor: 4.138

7.  Interaction between actin and the effector peptide of MARCKS-related protein. Identification of functional amino acid segments.

Authors:  F Wohnsland; A A Schmitz; M O Steinmetz; U Aebi; G Vergéres
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

8.  Mapping the interface between calmodulin and MARCKS-related protein by fluorescence spectroscopy.

Authors:  A Ulrich; A A Schmitz; T Braun; T Yuan; H J Vogel; G Vergères
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

9.  Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo.

Authors:  A Ho; S R Schwarze; S J Mermelstein; G Waksman; S F Dowdy
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

10.  In vivo protein transduction: delivery of a biologically active protein into the mouse.

Authors:  S R Schwarze; A Ho; A Vocero-Akbani; S F Dowdy
Journal:  Science       Date:  1999-09-03       Impact factor: 47.728

View more
  13 in total

Review 1.  Cell penetrating peptides: overview and applications to the delivery of oligonucleotides.

Authors:  F Said Hassane; A F Saleh; R Abes; M J Gait; Bernard Lebleu
Journal:  Cell Mol Life Sci       Date:  2009-11-07       Impact factor: 9.261

2.  Leishmania-induced repression of selected non-coding RNA genes containing B-box element at their promoters in alternatively polarized M2 macrophages.

Authors:  Anitra L Farrow; Tanu Rana; Mukul K Mittal; Smita Misra; Gautam Chaudhuri
Journal:  Mol Cell Biochem       Date:  2010-12-17       Impact factor: 3.396

3.  Mechanism of down-regulation of RNA polymerase III-transcribed non-coding RNA genes in macrophages by Leishmania.

Authors:  Tanu Rana; Smita Misra; Mukul K Mittal; Anitra L Farrow; Keith T Wilson; MacRae F Linton; Sergio Fazio; Ian M Willis; Gautam Chaudhuri
Journal:  J Biol Chem       Date:  2010-12-13       Impact factor: 5.157

4.  Calcium condensed LABL-TAT complexes effectively target gene delivery to ICAM-1 expressing cells.

Authors:  Supang Khondee; Abdulgader Baoum; Teruna J Siahaan; Cory Berkland
Journal:  Mol Pharm       Date:  2011-04-22       Impact factor: 4.939

5.  In silico structural characterization of protein targets for drug development against Trypanosoma cruzi.

Authors:  Carlyle Ribeiro Lima; Nicolas Carels; Ana Carolina Ramos Guimaraes; Pierre Tufféry; Philippe Derreumaux
Journal:  J Mol Model       Date:  2016-09-24       Impact factor: 1.810

6.  Design of protease-resistant pexiganan enhances antileishmanial activity.

Authors:  Manjusha M Kulkarni; Anna Karafova; Wojciech Kamysz; Bradford S McGwire
Journal:  Parasitol Res       Date:  2014-05       Impact factor: 2.289

7.  Scaffold proteins LACK and TRACK as potential drug targets in kinetoplastid parasites: Development of inhibitors.

Authors:  Nir Qvit; Deborah Schechtman; Darlene Aparecida Pena; Denise Aparecida Berti; Chrislaine Oliveira Soares; Qianqian Miao; Liying Annie Liang; Lauren A Baron; Christian Teh-Poot; Pedro Martínez-Vega; Maria Jesus Ramirez-Sierra; Eric Churchill; Anna D Cunningham; Andrey V Malkovskiy; Nancy A Federspiel; Fabio Cesar Gozzo; Ana Claudia Torrecilhas; Maria Julia Manso Alves; Armando Jardim; Ndao Momar; Eric Dumonteil; Daria Mochly-Rosen
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-02-12       Impact factor: 4.077

8.  Insights from the analysis of a predicted model of gp63 in Leishmania donovani.

Authors:  Ali Razzazan; Mohammad Reza Saberi; Mahmoud Reza Jaafari
Journal:  Bioinformation       Date:  2008-11-02

Review 9.  Dendritic Guanidines as Efficient Analogues of Cell Penetrating Peptides.

Authors:  Colin V Bonduelle; Elizabeth R Gillies
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-12

Review 10.  Cell-Penetrating Peptides for Antiviral Drug Development.

Authors:  Melaine Delcroix; Lee W Riley
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.